These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25897424)

  • 1. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
    Indira Chandran V; Eppenberger-Castori S; Venkatesh T; Vine KL; Ranson M
    Oncoscience; 2015; 2(3):207-24. PubMed ID: 25897424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
    Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
    Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
    BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
    Gilder AS; Natali L; Van Dyk DM; Zalfa C; Banki MA; Pizzo DP; Wang H; Klemke RL; Mantuano E; Gonias SL
    Sci Rep; 2018 Feb; 8(1):2982. PubMed ID: 29445239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
    Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
    Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Boudou E; Pouillart P; Thiery JP; de Cremoux P
    Int J Cancer; 2005 Mar; 114(2):291-8. PubMed ID: 15543615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
    Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
    Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
    Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
    Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
    Falkenberg N; Anastasov N; Schaub A; Radulovic V; Schmitt M; Magdolen V; Aubele M
    Oncotarget; 2015 Apr; 6(10):8103-14. PubMed ID: 25797271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
    Castagnoli L; Ladomery M; Tagliabue E; Pupa SM
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
    Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
    J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
    Hemsen A; Riethdorf L; Brünner N; Berger J; Ebel S; Thomssen C; Jänicke F; Pantel K
    Int J Cancer; 2003 Dec; 107(6):903-9. PubMed ID: 14601049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. uPAR: An Essential Factor for Tumor Development.
    Lv T; Zhao Y; Jiang X; Yuan H; Wang H; Cui X; Xu J; Zhao J; Wang J
    J Cancer; 2021; 12(23):7026-7040. PubMed ID: 34729105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.